key: cord-0778027-j21t4ozq authors: Chambergo‐Michilot, Diego; Barros‐Sevillano, Shamir; Rivera‐Torrejón, Oscar; De la Cruz‐Ku, Gabriel A.; Custodio, Nilton title: Factors associated with COVID‐19 in people with Parkinson’s disease: a systematic review and meta‐analysis date: 2021-06-09 journal: Eur J Neurol DOI: 10.1111/ene.14912 sha: 2b3a48270939ba03f4e4d3dba30e86f223207e11 doc_id: 778027 cord_uid: j21t4ozq BACKGROUND: There is debate as to whether there is an increased risk of COVID‐19 infection in people with Parkinson's disease (PD), possibly due to associated factors. This study aimed to systematically review the factors associated with COVID‐19 in people with PD. METHODS: A search was carried out in PubMed, Scopus, and Web of Science up to November 2020 (updated until 1 April 2021). Observational studies that analyzed factors associated with COVID‐19 in people with PD were selected and revised. RESULTS: The authors included six studies (four case‐controlled studies and two cross‐sectional studies) in the qualitative and quantitative syntheses. The authors found that the following factors were associated with COVID‐19 in people with PD: obesity (OR: 1.79, 95% CI: 1.07–2.99, I(2): 0%), any pulmonary disease (OR: 1.92, 95% CI: 1.17–3.15, I(2): 0%), COVID‐19 contact (OR: 41.77, 95% CI: 4.77 – 365.56, I(2): 0%), vitamin D supplementation (OR: 0.50, 95% CI: 0.30–0.83, I(2): 0%), hospitalization (OR: 11.78, 95% CI: 6.27–22.12, I(2): 0%), and death (OR: 11.23, 95% CI: 3.92–32.18, I(2): 0%). The authors did not find any significant association between COVID‐19 and hypertension, diabetes, cardiopathy, cancer, any cognitive problem, dementia, chronic obstructive pulmonary disease, renal or hepatic disease, smoking, and tremor. CONCLUSIONS: Meta‐analyses were limited by the number of events and some methodological limitations. Despite this, the authors assessed the available evidence, and the results may be useful for future health policies. Parkinson's disease (PD) is the second most frequent neurodegenerative disorder in the world behind Alzheimer's disease. The PD rate ranges from 113 to 873 cases per 100,000 people, and increases in line with aging, reaching a rate of 1132-3198 cases per 100,000 in people aged over 80 years [3] . The lowest prevalence has been reported in Asia, while the highest is in Europe. This may be due to the greater number of elderly people in Europe; however, considering only people aged over 80 years, South America has the highest prevalence of PD [3] . The impact of the COVID-19 pandemic has affected PD patients in different ways. The most expected way is the higher frequency of serious cases of COVID-19 due to the presence of a predominantly elderly population; moreover, the mandatory quarantine in some countries has also affected the population with PD in terms of worsening of symptoms. There is a debate about whether there is an increased risk of COVID-19 infection in people with PD. Two decades ago, researchers reported the presence of antibodies against coronavirus in the cerebrospinal fluid of patients with PD, suggesting a certain relationship between both entities [4] . In addition, the coronavirus uses the spike protein to interact with angiotensin-converting enzyme 2 (ACE2), for which COVID-19 has a higher affinity [5] . The latter is important because ACE2 is found in high quantities in dopaminergic neurons, which are decreased in people with PD, and may be another cause for the worsening of pre-existing symptoms or a more severe COVID-19 infection [6] . Besides, some researchers have hypothesized that an alteration of the dopamine synthetic pathways could be related to the pathophysiology of COVID-19, placing people with PD at a possibly higher risk of contagion [7] . It is undeniable that PD is associated with an elderly population; however, the outcomes obtained do not depend only on age, but on other factors, such as the presence of diabetes and arterial hypertension, which were found in higher proportions in the population with PD compared to the population without PD [8] . To date, a review has not yet been conducted that systematically addresses the search for factors associated with COVID-19 in people with PD. Therefore, we aimed to systematically review the available evidence on this topic. Reporting Items for Systematic Reviews and Meta-Analyses We searched for evidence up to 14 November 2020 in the following databases: PubMed, Scopus, and Web of Science. We updated the search up to 1 April 2021. The search strategies are available in Supplementary Material S1. We did not limit the search by publication date or language. We intended to include observational studies (cross-sectional studies, case-controlled studies, and cohorts) that analyzed factors associated with COVID-19 in people with PD. We excluded case reports, case series, reviews, letters to the editor, congress or conference abstracts, editorials, interviews, comments, and newspaper articles. One author (D.C.M.) downloaded all the references to an EndNote document in order to eliminate duplicates. Then, this author exported those references to the Rayyan QCRI webpage (https://rayyan.qcri. Two authors (D.C.M., S.B.S.) independently extracted the data of interest. For dichotomous outcomes, we extracted absolute and relative frequencies. The extraction was performed using a prepiloted Microsoft Excel sheet. Any disagreement was discussed and resolved by consensus. In the case of not reported data, we planned to contact with the articles' authors. Two authors (D.C.M., S.B.S.) assessed the methodological quality of included studies. We used the Newcastle-Ottawa Scale (NOS) or its adapted version for cross-sectional studies. The NOS assesses three domains: (1) selection of the study groups, (2) comparability of groups, and (3) exposure or outcome according to the study design. We gave one point for each item (two points for a comparability item) according to methodological adequacy. The NOS gives a maximum score of 9 points. We considered that a score of ≥7 meant low risk of bias, a score of 4-6 meant moderate risk of bias, and a score <4 meant high risk of bias. Any disagreement was discussed and resolved by consensus. Meta-analyses were performed using a random-effect model with the inverse variance method. We used the Paule−Mandel estimator and Hartung−Knapp−Sidik−Jonkman method for τ 2 and 95% confidence intervals (95% CIs) calculations, respectively [9, 10] . For dichotomous outcomes we used odds ratios (ORs) with their 95% CIs. For continuous outcomes we calculated the mean difference by subtracting the mean controls from the mean of cases. Heterogeneity was described with the I² statistic [11] . An I² <30%, I² 30-60%, and I² >60% defined low, moderate, and high heterogeneity, respectively. We pooled outcomes if occurring in at least two studies. If one or more outcomes could not be extracted from a study it was removed from the analysis. Meta-regressions could not be performed due to insufficient number of studies per metaanalysis. We conducted the analyses using the metabin and metacont functions of the meta library of R 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria; http://www.r-proje ct.org). After duplicate removal we screened 322 records. Finally, we included six studies in the qualitative and quantitative syntheses (Supplementary Material S2). Four of six manuscripts were casecontrol studies [8, [12] [13] [14] and the remainder were cross-sectional studies [6, 15] . Three studies assessed Italian people [8, 12, 13] , two studies assessed Spanish people [14, 15] and one paper studied people from all continents, with about 80% of respondents from the United States [6] . Only three studies reported PD criteria, and it was based on the Movement Disorder Society Clinical Diagnostic Criteria for PD. The case definition, or exposed people in the case of cross-sectional studies, was PD patients with COVID-19. The control definition, or non-exposed people in the case of crosssectional studies, was PD patients without COVID-19. The study of Brown, 2020 assessed adults with and without PD, and subdivided it by COVID-19 infection. Only two case-control studies reported matching factors, which were sex, age, and disease duration ( Table 1) . Regarding the characteristics of assessed subjects, the sample size ranged from 21 to 5429 subjects. The proportions of males and females were balanced between the cases and controls. The mean/ median age ranged from 65 (IQR: 40-89) to 75.9 (SD: 9.0) years in cases/exposed, and from 63.5 (SD: 12.6) to 75.05 (SD: 8.18) years in controls/non-exposed. Disease duration ranged from 6.3 (SD: 3.6) to 9.9 (SD: 6.4) years in cases/exposed, and from 6.1 (SD: 2.9) to 9.5 (SD: 6.8) years in controls/non-exposed ( and 0%-14.3% in cases/exposed, respectively, and 5.8%-10.9%, 0%-44.4%, 5.5%-12.0%, 2.0%-8.3%, and 0%-11.1% in controls/ non-exposed, respectively. Regarding PD-related symptoms, prevalence of tremor ranged from 50.0% to 73.3% in cases/exposed, and from 50.0% to 55.1% in controls/non-exposed. Three studies reported worsening of symptoms in the whole group (cases and controls). Following the onset of the pandemic, the prevalence Table 2) . Concerning the outcomes, hospitalization prevalence ranged from 17.1% to 57.14% in cases/exposed, and from 0% to 9.8% in controls/non-exposed. Death ranged from 0% to 21% in cases, and from 0% to 7.6% in controls/non-exposed (Table 2) . In our crude meta-analyses, we found that the following factors were associated with COVID-19 in people with PD: obesity (OR: Regarding case-control studies, two studies presented problems in the comparability domain since they did not control their analysis for important factors [8, 13] . None of these studies reported the nonresponse rate. Two of four studies presented a quality score lower than 7 points (Table 3) . Regarding cross-sectional studies, one study did not describe the non-response rate. The other study did not control its analysis for the most important factors. One of two studies presented a quality score lower than 7 points (Supplementary Material S6). First, we found that prevalence of COVID-19 in PD was 2%. Second, obesity, any pulmonary disease, hospitalization, and death were as- We found that pooled prevalence of COVID-19 in people with PD was 2%. In contrast, the reported prevalence in dementia patients was 13% [16] . First, dementia is a syndrome, therefore it accounts for PD and more neurodegenerative diseases. Second, the quantitative synthesis of this result comes from two studies, so the real TA B L E 3 Risk of bias assessment of included case-controlled studies occurs frequently in older adults and comorbid adults [1] as well as PD, therefore it may influence the prevalence of the disease in PD. More studies are needed to provide evidence as to the real estimate of COVID-19 in PD. Through our meta-analyses, we reported that obesity was an associated factor with COVID-19 in PD. This finding is consistent with the literature. Previous reports have shown that prevalence of obesity in COVID-19 is up to 61.3% [17] . Furthermore, previous papers have reported a potential association between obesity and the infection [18] . Obese people may present increased inflammatory cytokines that can alter the immune defense. Reduction in Th-2 and regulator cells has been reported, as well as an expansion of memory T-cells in fat tissue, and pro-inflammatory changes in the amount of adipokine, leptin, and adiponectin [18] , which increase the probability of infection. We reported that the presence of any other pulmonary disease in patients with PD was associated with COVID-19 cases. This is consistent with the literature in the general population [1] . Several pulmonary diseases injure the lung physiology, increase the risk of infection, and contribute to disease severity, such as asthma, which alters the immune system since innate and specific immunity are retarded, exacerbating the disease and increasing the risk of viral infection [19] . However, these results may not be sufficiently precise in terms of reality due to the small population in some included studies, such as that shown with chronic obstructive pulmonary disease, which was only reported in two studies [12, 13] , in one of which there was a population of 48 people and with a greater number of events in the group of people without COVID-19, a result contrary to that reported in other studies conducted in the general population without PD [13, 20] . We found that vitamin D supplementation was associated with lower cases of COVID-19 in PD. Similarly, a previous meta-analysis in adults with unknown PD prevalence showed that vitamin D deficiency in COVID-19 was higher than in non-COVID-19 patients [21] . Vitamin D modulates the adaptive response since it regulates excessive cytokine production [22] , β-defensins, and cathelicidins [23] , which have an important role in inactivating viruses [24] . Nevertheless, this crude pooled result comes from non-randomized studies, and a self-report variable; moreover, patients did not declare frequency, and dose and administration mode of vitamin D, so the pharmacological properties must have been heterogeneous. Our result only suggests a probable benefit that must be confirmed by future randomized studies. We found that a higher hospitalization rate was associated with the presence of COVID-19 in PD. Indeed, PD patients present a double risk of being admitted to hospital due to complications [25] . Likewise, in older adults, who are at higher risk of severe COVID-19, PD patients are at increased risk of comorbidities compared with non-PD patients [26] . Consequently, PD may predispose individuals to the risk of severe COVID-19, which leads to hospitalization. Furthermore, we found that mortality was associated with higher cases of COVID-19 in PD. This may be explained by the higher rate of intrahospital complications in PD patients, such as delirium, drug adverse effects, syncope, aspiration pneumonia, falls, and fractures [27] . Muscular weakness can early appear in PD [28] , and it could contribute to respiratory failure, which leads to death. On the one hand, after the pandemic onset, the prevalence of worsening of motor symptoms ranged from 29.6% to 41.13% [6, 8, 15] [6, 8, 15] . Despite the fact that social isolation is a measure for preventing SARS-CoV-2 infection, it may be a potential factor of worsening of PD symptoms [29] . In fact, living during the pandemic is an external psychological stressor, mainly for the elderly. This has been explored in other studies in the first months since the onset of the pandemic, which reported that one of the main concerns perceived by people with PD was the possibility of becoming infected with COVID-19, in addition to the need for an evaluation by their neurologist for a dose readjustment or by their physical therapist [30, 31] . Telemedicine has assumed an important role during the pandemic by permitting remote management [29] , however, it is not sufficient for PD patients since they require physical follow-up on account of their motor symptoms. More efforts are needed to control worsening symptoms, especially in PD patients living in remote areas. Our review has several limitations. There were chronic diseases, like hypertension, diabetes, and cardiopathies, which did not show a significant association with COVID-19 in PD. Meta-analyses were limited by the number of events; moreover, in some studies, the case−control matching was not reported, so there were methodological limitations. In contrast, the literature indicates that these comorbidities are associated with severe COVID-19 in not or unknown PD patients [2] . Another limitation is that studies did not separate the COVID-19 outcome by severity. Performing a subanalysis by severe COVID-19 might have better explained the plausibility of the association in some cases, such as obese patients. Moreover, metanalyses were not adjusted for confounders. Despite these limitations, we broadly assessed the available evidence, and our results may be useful for future health policies. None. Data available on request from the authors. Diego Chambergo-Michilot https://orcid. org/0000-0002-3904-7514 Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis The prevalence of Parkinson's disease: a systematic review and meta-analysis Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation The effect of the COVID-19 pandemic on people with Parkinson's disease Neurological complications of COVID-19 and possible neuroinvasion pathways: a systematic review Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region Methods to estimate the between-study 2 variance and its uncertainty in meta-analysis The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method Measuring inconsistency in meta-analyses COVID-19 in Parkinson's disease patients living in Lombardy Effects of COVID-19 on Parkinson's disease clinical features: a community-based casecontrol study COVID-19 in Parkinson's disease: what holds the key? Impact of COVID-19 pandemic on Parkinson´s disease: a cross-sectional survey of 568 Spanish patients Clinical presentation of COVID19 in dementia patients Obesity in patients with COVID-19: a systematic review and meta-analysis The impact of obesity on the immune response to infection Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis Modulation of the immune response to respiratory viruses by vitamin D Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression Epithelial defensins impair adenoviral infection: implication for adenovirus-mediated gene therapy Reasons for admission to hospital for Parkinson's disease Co-morbidity and polypharmacy in Parkinson's disease: insights from a large Scottish primary care database Hospitalisation and comorbidities in Parkinson's disease: a large Australian retrospective study Early occurrence of inspiratory muscle weakness in Parkinson's disease Management of advanced therapies in Parkinson's disease patients in times of humanitarian crisis: the COVID-19 experience Unmet needs of people with Parkinson's disease and their caregivers during COVID-19-related confinement: an explorative secondary data analysis Parkinson's disease patients' needs during the COVID-19 pandemic in a red zone: a framework analysis of open-ended survey questions Additional supporting information may be found online in the Supporting Information section. How to cite this article Parkinson's disease: a systematic review and meta-analysis